These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Vaginal rings for contraception: endocrine parameters.
    Author: Olsson SE.
    Journal: Adv Contracept Deliv Syst; 1992; 8(1-2):71-3. PubMed ID: 12285565.
    Abstract:
    Most of this review of the development of steroid-containing vaginal rings for contraception consists of a table listing drug dose, effect of the ring on bleeding and ovulation, and citation. The advantage of formulating a medicated vaginal ring is that the first-pass effect of an oral route of administration is avoided. Blood levels of the steroid are constant throughout the day. Low-dose progestin rings generally result in menstrual bleeding anomalies. Bleeding patterns improve when the progestin dose is raised and estradiol is added. A levonorgestrel ring developed by WHO has been fairly acceptable, with normal bleeding patterns in 50% of users, 365 ovulatory cycles, and pregnancy rates of 9.8% in women weighing 80 kg, and 1.7% in women 40 kg. Another approach is to combine progestin and estrogen. A ring releasing 120 or 150 mcg 3 keto-desogestrel and 15 mcg ethinyl estradiol daily has prevented ovulation and left bleeding patterns intact. The rings are used for 21 days, and removed for 7, and last 3 months. Generally about 70% of women find vaginal rings acceptable.
    [Abstract] [Full Text] [Related] [New Search]